Podcasts about therapeutics

We love to hear from our listeners. Send us a message.Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision medicine is headed as researchers pursue more effective treatments for patients with difficult-to-treat solid tumors, and more.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Send us Fan MailFor decades, the war on cancer has focused on destroying cancer cells directly - with chemotherapy, radiation, and targeted drugs. But what if the future of cancer treatment is not about attacking cancer ourselves...but teaching our own immune system to do it for us?Today we're exploring a new generation of immunotherapies designed to turn the body's own defenses into a precision weapon against cancer.Over the past decade, immunotherapies such as checkpoint inhibitors and CAR-T cell therapies have transformed the treatment landscape for many cancers. But major challenges remain - including limited response rates, treatment resistance, toxicity, and the enormous complexity and cost of manufacturing many next-generation therapies.Our guest today believes the next breakthrough may come from a new generation of personalized immunotherapies designed to activate a patient's own immune system against their cancer - while also being manufactured as an accessible, off-the-shelf treatment.Joining us is Dr. William Williams, MD - President and CEO of BriaCell Therapeutics ( https://briacell.com/ ).Dr. Williams brings more than 35 years of experience spanning academia and the biopharmaceutical industry. He has helped advance numerous medicines from discovery through clinical development, including work contributing to therapies such as Jakafi and Olumiant during his time at Incyte, and multiple oncology programs during his career at GlaxoSmithKline.Before entering industry leadership, Dr. Williams was a researcher at the University of Pennsylvania focused on molecular immunology, receptor biology, and early DNA vaccine approaches.Today we'll discuss the evolution of cancer immunotherapy, BriaCell's Bria-IMT platform, the challenges of treating advanced breast cancer, and whether the future of oncology lies in creating therapies that can truly mobilize each patient's own immune system.#CancerResearch #CancerImmunotherapy #Immunotherapy #CancerTreatment #Oncology #PrecisionMedicine #PersonalizedMedicine #Biotechnology #Biotech #LifeSciences #DrugDiscovery #ClinicalTrials #BreastCancer #MetastaticBreastCancer #CancerVaccine #CellTherapy #TumorImmunology #TCells #ImmuneSystem #MedicalInnovation #FutureOfMedicine #HealthcareInnovation #BiomedicalResearch #Pharma #PharmaceuticalInnovation #SciencePodcast #ProgressPotentialAndPossibilities #PPPShowSupport the show

Marina Better is a PhD candidate in Physiology, Pharmacology, and Therapeutics (formerly Pharmacology and Molecular Sciences) at Johns Hopkins University whose research focuses on maternal-fetal health, drug delivery, and translational therapeutics for pregnancy-related conditions. Her work explores innovative nanomedicine and drug delivery approaches to improve outcomes in preterm birth and reproductive health. Originally from Fayetteville, Marina began her scientific journey as an NIH-RISE and NSF-PrOMiSS scholar at Fayetteville State University before continuing her training at Johns Hopkins. She has authored multiple peer-reviewed publications, presented her research nationally and internationally, and is deeply committed to mentorship, scientific equity, and expanding opportunities for underrepresented students in biomedical research. The long-term goal of Marina's work is to improve maternal and fetal health through interdisciplinary research and innovation.linkedin.com/in/marina-better-10935b14b?utm_source=share_via&utm_content=profile&utm_medium=member_iosPresented to you by The No Static Network!

In this episode, Lisa welcomes Jess Draper, a holistic infant occupational therapist, IBCLC, and pelvic floor therapist based in Eugene, Oregon. Through her practice, Hali'a Therapeutics, Jess provides concierge-style care for families from pregnancy through the first year of life, bringing a whole-body, nervous-system-informed lens to feeding, oral motor function, movement, milestones, and tongue tie care.Lisa and Jess talk about the important role occupational therapy can play in infant feeding and tongue tie care, especially when babies are struggling with regulation, sensory processing, oral motor coordination, head shape, or feeding patterns that do not fit neatly into one category.Jess explains sensory processing in a practical way, including how babies take in, filter, and respond to touch, sound, movement, and oral input. They discuss how sensory differences may show up during feeding, such as gagging, popping on and off the breast, difficulty reorganizing after switching sides, or becoming easily overwhelmed by movement, sound, or touch.They also explore neuroplasticity, mirror neurons, and why babies often need support learning how to use new tongue mobility after release. Jess shares why infant care should include more than identifying restriction, and why supporting function, movement, and nervous system regulation can make such a difference.The conversation also includes an important discussion about head shape, palate shape, birth positioning, time in containers, and how the body's structure can influence feeding. Lisa and Jess emphasize the importance of looking at the whole baby, not just the mouth.Lisa and Jess discuss:How occupational therapy fits into infant feeding and tongue tie careWhat sensory processing means in babiesSigns that sensory overwhelm may be affecting feedingWhy some babies struggle with oral input, movement, or switching sidesNeuroplasticity, mirror neurons, and infant oral motor learningWhy babies may need help learning to use new tongue mobilityHow head shape and palate shape can affect feedingThe impact of birth positioning, prematurity, and time in containersWhy whole-body assessment matters before and after tongue tie releaseSupporting both baby and parent as a connected dyadConnect with Jess DraperInstagram: @haliatherapeuticsEmail: jess@haliaot.comMore from Tongue Tie ExpertsExplore additional resources, including downloads, free guides, and links mentioned in this episode—along with access to our courses and new book:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

In this week's episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Dr. Tanya Petrossian, CEO and Founder of EndoCyclic Therapeutics, a biopharmaceutical company developing a non-hormonal therapeutic approach for endometriosis. Endometriosis affects many women, but it is still often difficult to diagnose, treat and fully understand. For many patients, available treatment options have historically centered on hormone-based therapies or surgery, leaving significant unmet needs in long-term care. In this episode, Dr. Petrossian discusses the patient burden of endometriosis and why the condition has remained challenging to diagnose and treat. She also shares how her own experience with delayed diagnosis helped shape her understanding of the gaps patients face and ultimately contributed to her decision to start EndoCyclic Therapeutics. The conversation explores why innovation has lagged in endometriosis, despite the condition's significant impact on patients' lives. Dr. Petrossian discusses the need for new treatment options, including approaches that do not rely on hormones, and explains at a high level how EndoCyclic Therapeutics' work is designed to target disease biology. Dr. Petrossian also discusses the broader challenges and opportunities of building a company in women's health, including the progress being made in endometriosis research and the continued need for greater recognition, investment and clinical innovation. Tune in to learn more about endometriosis, the need for new treatment approaches and what progress in women's health innovation could look like in the years ahead. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Financials surging as investors countdown to second quarter bank earnings next week, expecting major growth. The traders break down what the results could mean for these names and whether banks will see major gains. Then, shares of Kymera Therapeutics soaring as its Eczema drug trial timeline moves faster than expected. The firm's founder, president and CEO Nello Mainolfi talks trial data and where the company is heading next. Plus, SpaceX stock plummeting despite bull calls on the Street, the media market under pressure, and Coke hitting all-time highs back to its century-old IPO. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailFor decades we've treated autoimmune diseases by suppressing the immune system - but what if we've been approaching the problem all wrong? What if, instead of lifelong immunosuppression, we could selectively eliminate the immune cells causing disease and allow the immune system to rebuild itself? Today we're exploring one of the hottest areas in biotechnology: T-cell engagers and the possibility of an "immune reset."Dr. Jeffrey Jones, MD, MPH is Chief Medical Officer of Cullinan Therapeutics ( https://cullinantherapeutics.com/ ) and one of the leaders helping bring the power of T-cell engager therapies beyond cancer and into autoimmune disease. With more than two decades of experience spanning academia and industry, Dr. Jones has been at the forefront of clinical development in hematology, oncology, and immunology.Prior to joining Cullinan, Dr. Jones served as Vice President of Global Drug Development at Bristol Myers Squibb, leading programs in lymphoma and myeloid diseases and helping guide the lifecycle strategy for Reblozyl®. Earlier, he held leadership positions at Celgene, where he developed clinical strategies across lymphoma and chronic lymphocytic leukemia portfolios.Before entering industry, Dr. Jones spent more than a decade at The Ohio State University, where he led the Chronic Lymphocytic Leukemia clinical research program and served as Associate Professor of Internal Medicine. Today, he is helping pioneer a new generation of T-cell engagers designed not to continuously suppress the immune system, but potentially to reset it - opening the possibility of durable, treatment-free remission for diseases such as rheumatoid arthritis, lupus, lupus nephritis, and autoimmune cytopenias.Dr. Jones earned his MD from the University of Michigan Medical School, an MPH from the University of Texas School of Public Health, and an MBA from The Ohio State University Fisher College of Business.#AutoimmuneDisease #Lupus #RheumatoidArthritis #Immunology #TCellEngagers #Biotechnology #DrugDevelopment #PrecisionMedicine #ImmuneSystem #ImmuneReset #ClinicalTrials #Biotech #HealthcareInnovation #FutureOfMedicine #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."   "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech MindMazeTherapeutics.com Listen to the podcast here

Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."   "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech MindMazeTherapeutics.com Download the transcript here

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer's drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!To begin the episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss recent advances in type 1 diabetes (T1D) research following presentations at the American Diabetes Association (ADA) Scientific Sessions and the American Association of Clinical Endocrinology (AACE) Annual Meeting. They focus on promising data from an islet cell transplantation study in which all 12 participants achieved insulin independence, with some maintaining normal glycemia for up to 2 years after transplantation.Isaacs explains that the transplanted islet cells restore endogenous insulin production and emphasizes that the study's most notable innovation is its immunosuppression strategy. Rather than relying on calcineurin inhibitors such as tacrolimus, which are associated with significant toxicities, particularly nephrotoxicity, the investigators used the investigational anti-CD40 ligand therapy tegoprubart. The hosts discuss how this approach may improve the long-term safety and feasibility of islet transplantation and note ongoing efforts to develop more convenient formulations beyond the current intravenous infusion administered every 3 weeks.The conversation then turns to the clinical significance of the findings. Bellini highlights that all 12 enrolled participants achieved insulin independence, distinguishing these results from earlier transplantation efforts such as the Edmonton protocol. The hosts also describe the substantial improvements in quality of life reported by participants, including sustained HbA1c values in the normal range without restrictive dietary practices and complete resolution of severe hypoglycemia. Because the trial enrolled individuals with recurrent, life-threatening hypoglycemia, they emphasize that the observed benefits are particularly meaningful for this high-risk population.The hosts also examine several unanswered questions that remain before this approach can become widely available. They discuss the durability of insulin independence, the long-term need for immunosuppressive therapy, treatment costs, and the challenges associated with scaling islet transplantation beyond specialized research centers. Additional findings are reviewed, including the need for repeat transplantation in 2 participants and observations suggesting that individuals with higher body mass index may require greater islet mass to achieve insulin independence. They also discuss the use of tirzepatide in 2 participants, raising questions about the role of insulin resistance and adjunctive therapies following transplantation.Broadening the discussion, Isaacs and Bellini review several emerging strategies aimed at expanding access to curative therapies. These include stem cell-derived islets, large-scale beta cell manufacturing, gene-editing approaches, and encapsulation technologies intended to protect transplanted cells while reducing or eliminating the need for chronic immunosuppression. Drawing on presentations from Aaron Kowalski, PhD, and Laura Jacobsen, MD, they emphasize that despite major advances in continuous glucose monitoring, automated insulin delivery systems, and adjunctive pharmacotherapy, subcutaneous insulin administration remains fundamentally nonphysiologic and cannot fully eliminate long-term complications or disease burden.The episode concludes with a broader discussion of the future of type 1 diabetes research. The hosts highlight efforts to expand eligibility for islet transplantation trials, including studies involving individuals with chronic kidney disease who were previously excluded because of concerns surrounding traditional immunosuppressive therapies. They also underscore the importance of continuing to pursue disease-modifying therapies despite improvements in diabetes technology, emphasizing that glycemic targets alone do not eliminate complications or address disparities in access to care. While acknowledging that a universally applicable cure remains years away, Isaacs and Bellini conclude that the field is making meaningful progress toward safe, durable, and scalable therapies capable of fundamentally changing the treatment of type 1 diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Thalia Therapeutics (AIM:THAT) CEO Dr David Solomon joined Proactive's Stephen Gunnion to discuss the acquisition of Sanmirna Therapeutics and how it transforms Thalia into a clinical-stage RNA therapeutics business. The deal brings clinical-stage asset miRisten into Thalia's portfolio, adding a Phase 1 trial currently recruiting AML patients at City of Hope. miRisten targets miR-126, a microRNA associated with disease progression. Solomon explained that reducing it may slow AML while making leukaemia stem cells more susceptible to existing treatments such as Venetoclax and chemotherapy. The acquisition advances Thalia's timeline by more than seven years compared with developing a similar asset in-house, with top-line trial results expected by H1 2027 and interim data before that. "This deal transforms Thalia into a clinical stage company overnight," he said. A £2.75 million fundraise alongside the deal is expected to fund the trial through to readout, with strong backing from directors, vendors and institutional investors. The interview also covers Thalia's broader pipeline, including its cardiovascular gene-silencing programme and the Nuvec delivery technology. For more interviews and market insights, visit the Proactive YouTube channel. Please like this video, subscribe to the channel and enable notifications so you never miss future content. #ThaliaTherapeutics #DavidSolomon #miRisten #AML #AcuteMyeloidLeukaemia #RNAtherapeutics #MicroRNA #Biotech #HealthcareInvesting #AIMMarket #ClinicalTrials #CityOfHope #DrugDevelopment #GeneSilencing #LifeSciences

Guests:Martin Wikelski, Director at the Max Planck Institute of Animal BehaviorAndrea Kwakowsky, Associate Professor of Pharmacology & Therapeutics at the University of Galway

On today's episode, we welcome Dr. Stephanie Venn-Watson, Co-Founder and Co-CEO of Seraphina Therapeutics, the company behind Fatty15. Stephanie is a veterinary epidemiologist, author of The Longevity Nutrient, and one of the world's leading experts on C15:0 — the first essential fatty acid discovered in over 90 years. Stephanie's story starts in an unexpected place: studying aging Navy dolphins. While working to improve their long-term health, she and her team discovered C15:0, a fatty acid that may play a critical role in strengthening cells and supporting healthy aging. That discovery led to years of research, more than 100 peer-reviewed studies, dozens of patents, and ultimately Fatty15 — a science-backed supplement designed to support cellular health, longevity, and overall wellness. In this episode, Stephanie shares how a breakthrough in dolphin health became a human health innovation, why she believes we have misunderstood certain saturated fats for decades, and what consumers should know about C15:0, cellular fragility, and healthy aging. We also talk about building trust in the crowded wellness space, turning serious science into a consumer brand, and why some of the biggest discoveries come from questioning what everyone assumes is true. This episode is a must listen!   Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks.   To learn more about Dr. Stephanie Venn-Watson and Fatty15:https://www.linkedin.com/in/stephanievennwatson/https://www.instagram.com/fatty15/https://www.fatty15.com/   Sponsored By: AT&T Business - Switch to AT&T Business at business.att.com Zocdoc - Go to Zocdoc.com/KARA to find and instantly book a doctor you love today. RULA - Go to Rula.com/KARAGOLDIN for convenient therapy that's covered by insurance. LinkedIn Jobs - Head to LinkedIn.com/KaraGoldin to post your job for free.   Check out our website to view this episode's show notes: https://karagoldin.com/podcast/856

Selena Freisens, Head of Global Medical Affairs at Merz Therapeutics, is focused on increasing access to tools to support neurological health. They have developed a digital app iFlexo, which is designed to provide at-home physiotherapy for stroke survivors.  The app has been tested in Nigeria and Sierra Leone in partnership with the World Stroke Organization and is designed to operate offline as well, to serve users in rural areas with limited internet connectivity. Selena explains, "Our company is family-owned and in its fifth generation, so we have a rather long-term legacy, and the newer part is Merz Therapeutics, and our focus in Merz Therapeutics is on neuroscience. So we practically cover the number of movement disorders such as Spasms, Dystonias. We also have a focus on Parkinson's and Multiple Sclerosis."   "We continuously work on building this awareness and knowledge. One example is Parkinson's disease. And when I started working with Parkinson's disease, most of the patients would have off episodes, which are exacerbations of their symptoms, but many of these off episodes are underdiagnosed, and they're not really treated optimally. So it's really a lot of attention is needed to educate not only HCPs and, of course, some other stakeholders, but particularly patients."   "So the time also matters for stroke survivors. So it's very important that they start as soon as possible all the therapies, but also the physiotherapy at the same time. What this digital tool does is give two options. One is education on the one side, and on the other hand, a guided exercise that will enable people and stroke survivors to exercise at home. And with that, obviously, the personalized goals have been worked out together with the experts and HCPs so that they can achieve those goals faster, while working from home." #MerzTherapeutics #StrokeRehab #DigitalHealth #NeuroRehab #AccessToHealth #WorldStrokeOrganization #Physiotherapy #HealthEquity #TeleRehab #HCPs #Africafirst #AccesstoHealth #EquitableAccess #PostStrokeRehabilitation #PatientDrivenInnovation Merztherapeutics.com Download the transcript here

Selena Freisens, Head of Global Medical Affairs at Merz Therapeutics, is focused on increasing access to tools to support neurological health. They have developed a digital app iFlexo, which is designed to provide at-home physiotherapy for stroke survivors.  The app has been tested in Nigeria and Sierra Leone in partnership with the World Stroke Organization and is designed to operate offline as well, to serve users in rural areas with limited internet connectivity. Selena explains, "Our company is family-owned and in its fifth generation, so we have a rather long-term legacy, and the newer part is Merz Therapeutics, and our focus in Merz Therapeutics is on neuroscience. So we practically cover the number of movement disorders such as Spasms, Dystonias. We also have a focus on Parkinson's and Multiple Sclerosis."   "We continuously work on building this awareness and knowledge. One example is Parkinson's disease. And when I started working with Parkinson's disease, most of the patients would have off episodes, which are exacerbations of their symptoms, but many of these off episodes are underdiagnosed, and they're not really treated optimally. So it's really a lot of attention is needed to educate not only HCPs and, of course, some other stakeholders, but particularly patients."   "So the time also matters for stroke survivors. So it's very important that they start as soon as possible all the therapies, but also the physiotherapy at the same time. What this digital tool does is give two options. One is education on the one side, and on the other hand, a guided exercise that will enable people and stroke survivors to exercise at home. And with that, obviously, the personalized goals have been worked out together with the experts and HCPs so that they can achieve those goals faster, while working from home." #MerzTherapeutics #StrokeRehab #DigitalHealth #NeuroRehab #AccessToHealth #WorldStrokeOrganization #Physiotherapy #HealthEquity #TeleRehab #HCPs #Africafirst #AccesstoHealth #EquitableAccess #PostStrokeRehabilitation #PatientDrivenInnovation Merztherapeutics.com Listen to the podcast here

References Cell Death & Disease 2018. v. 9, Article number: 600CNS Neuroscience & Therapeutics 2009. 15:32–51Oncol Lett 2016 Aug;12(2):897-903.Cell Death Discovery  2025V 11, Article number: 489 Biomedicine & Pharmacotherapy2024 v. 172, March 116229Guerra, DJ. 2026. Unpublished Lectures.Lennon/McCartney.1968. I'm So Tired. White Album-Beatleshttps://open.spotify.com/track/2X9H5BokS1u5O46YpNYNsZ?si=bdcc11350bc24d90Dubin/Warren. 1935.Lullaby of Broadway -Doris Day.(1951).https://open.spotify.com/track/4hG3Xgm6H4ELBi8ESQoosr?si=b5a84bdc0be84dbc

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

What does the future of hearing restoration look like? Are we approaching a world where hearing loss can be treated with pharmaceuticals rather than simply managed with hearing aids?Originally presented at the Future of Hearing Healthcare (FHH2026) conference, this expert panel explores the latest advances in inner ear therapeutics and what they could mean for the future of hearing healthcare.Topics discussed include:The recent momentum in inner ear therapeutics and gene therapyPreventing chemotherapy-induced hearing lossNew treatments for Ménière's disease, tinnitus, and age-related hearing lossWhy better diagnostics and AI may transform hearing healthcareThe challenges of drug delivery to the inner earThe role of small molecules versus gene and cell therapiesHow therapeutics may change the future role of audiologists and hearing care professionalsWhat the panelists are most optimistic about over the next decadePanelists:Dr. Brian Taylor (Moderator)Jonas Dürfjeld Johnsen – Acousia TherapeuticsHugo Peris – Spiral TherapeuticsJonathan Kil – Sound PharmaceuticalsCelia Belline – CilcareFrom breakthrough science to real-world clinical implications, this discussion provides a fascinating look at one of the fastest-evolving areas in hearing healthcare and what it could mean for millions of people living with hearing loss.Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.https://x.com/WeekinHearinghttps://www.instagram.com/thisweekinhearing/https://www.linkedin.com/company/this-week-in-hearingVisit us at: https://hearinghealthmatters.org/thisweek/

Messenger RNA (mRNA) plays a literally central role in the functioning of life as we know it, shuttling information back and forth between the DNA where it is stored to the ribosome where it is used to produce proteins. RNA may even have been the first molecule to kick-start the origin of life. Today, scientists are learning how to manipulate mRNA to cure and prevent diseases, whether through vaccination or literally editing one's DNA. Jeff Coller explains how it all works and how mRNA is revolutionizing medicine as we know it. Blog post with transcript: https://www.preposterousuniverse.com/podcast/2026/06/15/357-jeff-coller-on-mrna-vaccines-and-bespoke-therapeutics/ Support Mindscape on Patreon. Jeff Coller received his Ph.D. in cell and molecular biology from the University of Wisconsin-Madison. He is currently Bloomberg Distinguished Professor of Biomedical Engineering and Director of the RNA Innovation Center at Johns Hopkins University. He is co-founder of Tevard Biosciences and the Alliance for mRNA Medicines, and leads the REPAIRx consortium. He is a fellow of the American Association for the Advancement of Science. Web site Johns Hopkins web page Google Scholar publications "This May Be the Most Important Medical Story of the Decade," New York Times, April 9, 2026

We love to hear from our listeners. Send us a message.In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA. He also shares why in vivo therapies still need to prove precision, durability, and predictability before they become mainstream, and why the field must move beyond proof of concept to reproducible clinical performance across patients and diseases. He discusses the importance of patient selection, tissue specificity, and matching editing efficiency to biological thresholds, and much more. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

The use of biotherapies has surged in recent years, creating new challenges and opportunities for pharmacy. In this episode, three experienced pharmacists in the world of biotherapeutic drugs will review key considerations for working with these agents. Their discussion will cover biosafety review processes and how to develop the structure to support ongoing management of biotherapeutics. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

A non-invasive Alzheimer's therapy is moving closer to patients, and it could reshape how brain health is treated. In this episode, Christian Howell, CEO of Cognito Therapeutics, joins Saul live at DeviceTalks Boston to discuss how the company is advancing a novel Alzheimer's therapy that uses sensory stimulation through light, sound, and touch. He shares insights from Cognito's HOPE study, the largest non-pharmacologic clinical trial in neurodegenerative disease, involving 673 participants across 70 sites. Christian explains why a strong evidence strategy is essential not only for regulatory approval but also for reimbursement, clinical adoption, and patient access. He also reflects on leadership lessons centered on service, humility, humor, and the importance of aligning stakeholders across the healthcare ecosystem to improve Alzheimer's care. Tune in to hear how Christian Howell and Cognito Therapeutics are working to bring new hope, stronger evidence, and a more accessible path forward for Alzheimer's patients and families! Resources: Connect with and follow Christian Howell on LinkedIn. Follow Cognito Therapeutics on LinkedIn and explore their website.

Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations. This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Alissa Coram and Ed Carson walk through Tuesday's market action and discuss key stocks to watch in Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Sotirios Stergiopoulos, Chairman of Coiled Therapeutics, to discuss the company's recent progress and strategic developments. The conversation covers advances in its oncology programme, the strengthening of its scientific team, upcoming milestones, and the broader opportunities ahead as the company continues to develop its innovative therapeutic platform.Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

We love to hear from our listeners. Send us a message.In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company's mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting pathogenic B cells and enabling a broad immune reset, differentiating it from conventional therapies that require ongoing management. As Kyverna advances a rolling BLA submission, Dr. Gehchan positions this milestone as potentially historic, both for SPS patients and for the broader cell therapy field, signaling an inflection point where CAR T could transform autoimmune disease care in the same way it has oncology.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.This episode is brought to you by:Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase) Incogni, which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the AI Agent & Copilot Podcast, Giuseppe Ianni, AI Practice Lead and industry thought leader, is joined by Nandita Puri, PhD Candidate at Georgia Tech and founder of Illumia.bio. Puri discusses how AI is transforming drug discovery by creating massive therapeutic libraries, connecting fragmented biomedical knowledge, and dramatically accelerating research timelines. Their conversation explores the convergence of AI, structural biology, and life sciences. Key Takeaways AI Expands the Search Space for New Therapeutics: Traditional drug discovery focuses on identifying a single drug for a single target, but Puri argues that diseases are complex biological systems requiring broader approaches. Her team is building an AI-generated library of more than 10 billion molecules across multiple therapeutic modalities. By treating drug discovery as a combinatorics problem, researchers can explore vastly larger therapeutic possibilities. Connecting Fragmented Scientific Knowledge Accelerates Discovery: One of the biggest bottlenecks in pharmaceutical research is the fragmented nature of scientific information. Researchers often spend years reviewing hundreds of papers before forming a hypothesis. Puri describes how her team is integrating 60 to 70 public databases into a connected knowledge platform that links diseases, genes, proteins, pathways, and drug candidates. As she notes, "When we type a disease, we know exactly the gene, we exactly know the protein." This consolidation dramatically reduces research time and enables scientists to make more informed decisions earlier in the discovery process. AI Creates New Opportunities for Rare Disease Research: Rare diseases have historically been underserved because of the high costs and long timelines associated with traditional drug development. Puri says that bringing a drug to market can require "$1 billion and about 10 years." By shortening research cycles from years to months, AI lowers the barriers to investigating diseases that pharmaceutical companies may have previously avoided. This acceleration enables smaller teams to pursue treatments for conditions affecting fewer patients while increasing the likelihood that promising therapies can move forward to validation and clinical testing. Visit Cloud Wars for more.

Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological micropancreas that could one day offer a one-time cure for insulin-dependent diabetes — replacing the missing pancreatic function with living cells that sense glucose and respond in real time. Avraham sat down with Racheli to discuss how the technology works, what their animal trials showed, why IP is critical, the challenges of funding a biotech startup in wartime Israel, her advice for founders just getting started and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/ betalin. Listen to all of the episodes at https://jmbdavis.com/podcast.

Pancreatic cancer is a devastating diagnosis, and the statistics are alarming. According to the latest research, it's the third leading cause of cancer-related deaths in the US, with over 50,000 people losing their lives each year. The disease is particularly aggressive, with a survival rate of just six to seven months after diagnosis. In this episode, our guest, Dr. Greg Verdine, shares his insights on a promising new treatment that could reshape the way we approach pancreatic cancer. Dr. Verdine, a professor of chemistry at Harvard and CEO of LifeMine Therapeutics, discusses the challenges of treating pancreatic cancer, including its tendency to be asymptomatic until late stages and its resistance to chemotherapy. He explains how a new daily pill, currently in early trial stages, targets the cancer's genetic mutations and has shown promising results in extending patients' lifespans. The conversation delves into the complexities of pancreatic cancer, including its unique characteristics that make it difficult to treat. Dr. Verdine highlights the importance of this new treatment, which has the potential to double patients' lifespans and pave the way for further research. If you're interested in learning more about this breakthrough treatment and the future of pancreatic cancer research, tune in to this episode to hear Dr. Verdine's expert insights and the potential for a brighter outlook on this devastating disease.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

What does it really take to progress from bench science to leading a Biotech platform as Chief Scientific Officer? In this episode of Careers in Discovery, Daniel Tardiff, CSO at Camp4 Therapeutics, shares a candid look at building and scaling science inside an early‑stage biotech. From his foundations in RNA biology to advancing antisense programmes for haploinsufficiency-driven neurodevelopmental disorders, Dan unpacks how translational judgement is developed over time, not taught. Key takeaway: Career progression isn't about having perfect answers. It's about making credible decisions under uncertainty and bringing others with you as the science scales.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

A conversation with Dr. Babak Kateb Find the video of this conversation at https://youtu.be/GbnIhjO_Af0 Find more at https://www.worldbrainmapping.org/

We love to hear from our listeners. Send us a message.In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, to explore how allogeneic CAR-T is evolving from a scalability promise into an earlier-line, potentially curative intervention. Their conversation centers on the ALPHA3 trial, where MRD-guided treatment is redefining when and how CAR-T can be deployed, alongside broader implications for diagnostics, patient access, and the shift toward off-the-shelf therapies in community settings.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

This interview is disseminated on behalf of Cardiol Therapeutics Inc.In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.Learn more: https://www.cardiolrx.comWatch the full YouTube interview here: https://youtu.be/NXkzgfWHQnAAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia 

In this episode of Careers in Discovery, Adrian Gabriel Torres, Chief Scientific Officer at Aptadel Therapeutics, talks about developing RNA aptamer–based cancer therapies and leading scientific strategy in a preclinical biotech start-up. Adrian also shares his journey from academic research into industry, reflecting on the differences between academia and biotech, learning new skill sets, managing teams, and making career decisions along the way.

Rakhi Melvani, M.D., board-certified cornea and cataract and refractive surgeon at Gordon Schanzlin New Vision Institute, joins the Eye on Innovation podcast with host Carey Powers, M.B.A. to discuss innovative corneal treatments and how they're changing the way patients receive treatment. Their conversation explores the FDA approval of Epioxa, an epithelium-on corneal collagen cross-linking therapy to treat progressive keratoconus, as well as refractive surgery and dry eye therapies.   In this episode, learn about:  Ray tracing-based customization technology and how it's different from Lasik Collagen mimetic peptides and how they work ST100 and the patients that would benefit from it  RESOURCES:  Carey Powers: https://ois.net/carey-powers/  

Dr Simon Dean is an ophthalmologist based in New Zealand with a keen interest in optoelectronics. In 2007 he was awarded fellowship of the Royal Australian and New Zealand College of Ophthalmologists (FRANZCO). He completed fellowship training in the UK in oculoplastics and ocular oncology in Glasgow, followed by cataracts and anterior segment in Birmingham, UK, and the Bedford branch of Moorfields Eye Hospital. He also holds fellowship of the British Contact Lens Association (FBCLA) by examination. He completed his MSc in cataract and refractive surgery in 2009. Dr Dean was Head of Department at Manukau Superclinic for seven years, and consults privately through re:vision a boutique cataract and refractive clinic in Auckland. He was the Subject Leader for the RANZCO Optics exam team for 12 years and recently promoted within the College to Chair of the basic sciences and COPEM. Dr Dean is active in teaching and research and has designed and built a number of ophthalmic instruments, including a corneal collagen crosslinking device. He is inventor of the Photon Therapeutics device having built the first prototypes and coordinated the research to support this novel technology. When he is not accompanying his two boys to their many extracurricular activities, he can be found either on a mountain bike, climbing, or playing double bass in the St Matthews Chamber Orchestra. He is married to ocular surface research pioneer Professor Jennifer Craig.Check out Photon TherapeuticsCome check us out at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ashburton Eyecare⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/ashburton.eyecare/Instagram https://www.instagram.com/ryanoconnornz/  Instagram https://www.instagram.com/stagryan/  Twitter https://twitter.com/stagryan  Tik Tok @ryanstagoconnor  Facebook https://www.facebook.com/WaiKeto/  Blog https://stagryan.com/

Send us Fan MailFor decades, Parkinson's patients have been offered only symptom management. No drug has ever slowed the disease itself. A small clinical stage biotech may be about to change that.Gene Mack, CEO, Gain Therapeutics joins host David E. Williams to discuss the science behind a potential first disease modifying therapy for Parkinson's, how AI is accelerating drug discovery, and what it takes to build a biotech in one of the toughest capital markets in years.

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), and the Inflation Reduction Act (IRA). We also discuss Dr. Niazi's current company, RNA Therapeutics, and his quest to make new drug modalities accessible to patients around the world.     This episode of the Business of Biotech is brought to you by Cytiva. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/